Amgen's Sensipar EVOLVE trial misses goal on CV outcomes benefit
This article was originally published in Scrip
Amgen has suffered a setback in its bid to add a cardiovascular outcomes benefit to its oral calcimimetic agent, cinacalcet (Sensipar in the US; Mimpara outside the US). In announcing top-line results from its Phase III EVOLVE trial, the company said the trial did not meet its endpoint. The drug is already approved to treat secondary hyperparathyroidism in patients with chronic kidney disease receiving dialysis.